IREB2 and breast carcinoma: Importantly, these effects were consistently observed not only in parental radiation-insensitive (RI) cells but also in reprogrammed resistant (RR) cells, supporting the therapeutic potential of IRP2 inhibition as a strategy to overcome resistance during radiotherapy in breast cancer.